Table 2.
Levels of antibodies at the first episode of clinical malaria (acute) and one month later (convalescence) in relation to the levels of antibodies at the immediately preceding cross-sectional visit (pre-acute) in the three study groups
|
Antibody |
Antigen |
Pre-acute |
Acute |
Convalescent |
|
||||
|---|---|---|---|---|---|---|---|---|---|
| GM 1 | GM | Prop. diff. 2 | 95% CI | GM | Prop. diff. | 95% CI | P value 3 | ||
| IgG |
MSP-119 |
0.47 |
0.73 |
1.56 |
1.20; 2.02 |
3.02 |
6.39 |
4.86; 8.40 |
< 0.0001 |
| AMA-1 |
0.56 |
0.50 |
0.88 |
0.71; 1.09 |
1.01 |
1.80 |
1.44; 2.25 |
< 0.0001 |
|
| EBA-175 |
0.53 |
0.41 |
0.77 |
0.65; 0.91 |
0.56 |
1.04 |
0.87; 1.24 |
< 0.0013 |
|
| VSA |
17.46 |
8.60 |
0.49 |
0.27; 0.91 |
11.58 |
0.64 |
0.39; 1.06 |
< 0.0398 |
|
| IgM |
MSP-119 |
0.45 |
0.68 |
1.50 |
1.29; 1.73 |
0.67 |
1.47 |
1.26; 1.72 |
< 0.0001 |
| AMA-1 |
0.39 |
0.44 |
1.11 |
0.99; 1.26 |
0.48 |
1.23 |
1.08; 1.39 |
< 0.0083 |
|
| EBA-175 |
0.42 |
0.49 |
1.14 |
1.03; 1.26 |
0.51 |
1.18 |
1.06; 1.31 |
< 0.0046 |
|
| IgG1 |
MSP-119 |
0.30 |
0.47 |
1.54 |
1.16; 2.04 |
2.32 |
7.48 |
5.54; 10.1 |
< 0.0001 |
| AMA-1 |
0.37 |
0.31 |
0.82 |
0.65; 1.04 |
0.64 |
1.73 |
1.35; 2.22 |
< 0.0001 |
|
| EBA-175 |
0.31 |
0.21 |
0.69 |
0.59; 0.81 |
0.27 |
0.87 |
0.74; 1.03 |
< 0.0001 |
|
| IgG3 |
MSP-119 |
0.11 |
0.15 |
1.30 |
0.99; 1.70 |
0.49 |
4.36 |
3.28; 5.78 |
< 0.0001 |
| AMA-1 |
0.14 |
0.13 |
0.93 |
0.77; 1.12 |
0.29 |
2.04 |
1.66; 2.50 |
< 0.0001 |
|
| EBA-175 | 0.11 | 0.07 | 0.61 | 0.52; 0.72 | 0.09 | 0.80 | 0.67; 0.95 | < 0.0001 | |
1Geometric means.
2The proportional difference is the ratio between the average levels of antibodies from acute (or convalescent) samples vs the levels from pre-acute samples, taking into account repeated measures for children.
3P value from Mixed-effects linear regression models using Likelihood Ratio Test.